CFON-026 [CAS 2941611-57-8]

CFON-026 is a selective, orally active and non-covalent BTK inhibitor with an IC50 of 0.27 nM. CFON-026 has significant antitumor activity against wild-type BTK (TMD8 and REC-1) and all clinically relevant BTK resistance mutations (BTK C481S, T474I, L528W and V416L) . CFON-026 induces complete tumor regression in TMD8 xenograft mice model. CFON-026 can be used for research of hematological cancers like chronic lymphocytic leukemia and waldenström macroglobulinemia[1].

[2941611-57-8]

C33H34N8O2

574.68

NC1=NC=C2/C=C/CCCCCC(N[C@@H]3CCC[C@@H](C4=NC(C5=CC=C(C(NC6=CC(C#N)=CC=N6)=O)C=C5)=C1N24)C3)=O

Btk

Room temperature